Vascular Biogenics Ltd. (VBLT)의 가격은 얼마입니까?

Vascular Biogenics Ltd. (VBLT)의 가격은 $0.155입니다.

Vascular Biogenics Ltd. (VBLT)의 시가 총액은 무엇입니까?

Vascular Biogenics Ltd. (VBLT)의 시가 총액은 $7.44M입니다.

Vascular Biogenics Ltd. (VBLT) 영업이익률

Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical company, dedicated to developing therapeutic solutions for cancer and immune-inflammatory diseases. The company's activities are concentrated in Israel and the United States. Its pipeline is anchored by two core technological platforms: First, a gene-based vascular targeting system that focuses on newly formed blood vessels; and second, an antibody-based monocyte targeting technology that aims to specifically inhibit monocyte migration, particularly for immune-inflammatory applications. VBLT's flagship product candidate, VB-111, a gene-based biologic, is undergoing several clinical trials. It has reached Phase III for the treatment of recurrent, platinum-resistant ovarian cancer. Additionally, it is in Phase II trials for recurrent glioblastoma and colorectal cancer. Moreover, VB-111 has completed Phase II clinical trials for thyroid cancer. The company is also developing VB-601 for a variety of inflammatory indications and VB-611 for different types of solid tumors. Initially incorporated as Medicard Ltd. in 2000, the company rebranded as Vascular Biogenics Ltd. in January 2003. Its main offices are situated in Modi'in, Israel.

연도	영업이익률	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

영업이익률

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	영업이익률	영업이익률 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR
UCB S.A. UCB.BR	31.23%	-	BE

회사

영업이익률

영업이익률 차이

국가